Chronic Kidney Disease (CKD) Drugs Market – Global Industry Analysis, Size, Share, Trends and Forecast 2017 – 2023

Global Chronic Kidney Disease (CKD) Drugs market is expected to grow from $12.87 billion in 2016 to reach $16.13 billion by 2023 with a CAGR of 3.2%

PUNE, INDIA, December 11, 2017 /EINPresswire.com/ — Global Chronic Kidney Disease (CKD) Drugs Industry

Latest Report on Chronic Kidney Disease (CKD) Drugs Market Global Analysis & 2023 Forecast Research Study

Global Chronic Kidney Disease (CKD) Drugs market is expected to grow from $12.87 billion in 2016 to reach $16.13 billion by 2023 with a CAGR of 3.2%. Drivers that are shaping the global market include, growing incidences of chronic kidney diseases, rise in aged population, rising incidence of diabetes and obesity related disorders, significant unmet requirements and beneficial reimbursement policies. On the other hand, factors such as intense competition from biosimilars and growing preferences of generic drugs are creating a negative impact on the market growth.

By end user, the hospital segment is anticipated to dominate the market globally. North America leads the global market with a largest market share driven by huge acceptance of advanced technological products.

Some of the key players profiled in this market include Hoffmann-La Roche Ltd., GlaxoSmithKline plc., Teva Pharmaceutical Industries Ltd., Sanofi S.A., AstraZeneca plc, Pfizer, Inc., Amgen Inc., Kissei Pharmaceutical Co., Ltd, AbbVie, Inc., Keryx Biopharmaceuticals, Inc., Allergan plc., FibroGen Inc and Johnson & Johnson.

Try Sample Report @ https://www.wiseguyreports.com/sample-request/1631165-chronic-kidney-disease-ckd-drugs-global-market-outlook-2017-2023

End Users Covered:
• Specialty Clinics
• Hospitals

Drug Classes Covered:
• Calcium channel blockers
• Antihypertensive
• Anemia Treatment Drugs
• Antihyperlipidemic
• Erythropoiesis-stimulating agents (ESAs)
• Swelling Treatment Drugs
• Beta blockers
• Diuretics
• Angiotensin-II receptor blockers
• ACE Inhibitors
• Other Drug Classes

Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o France
o Italy
o UK
o Spain
o Rest of Europe
• Asia Pacific
o Japan
o China
o India
o Australia
o New Zealand
o Rest of Asia Pacific
• Rest of the World
o Middle East
o Brazil
o Argentina
o South Africa
o Egypt

What our report offers:
– Market share assessments for the regional and country level segments
– Market share analysis of the top industry players
– Strategic recommendations for the new entrants
– Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets
– Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
– Strategic recommendations in key business segments based on the market estimations
– Competitive landscaping mapping the key common trends
– Company profiling with detailed strategies, financials, and recent developments
– Supply chain trends mapping the latest technological advancements

For Detailed Reading Please visit WiseGuy Reports @ https://www.wiseguyreports.com/reports/1631165-chronic-kidney-disease-ckd-drugs-global-market-outlook-2017-2023

Some Major Points from Table of content:

1 Executive Summary

2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions

3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 End User Analysis
3.7 Emerging Markets
3.8 Futuristic Market Scenario

4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry

5 Global Chronic Kidney Disease (CKD) Drugs Market, By End User
5.1 Introduction
5.2 Specialty Clinics
5.3 Hospitals

6 Global Chronic Kidney Disease (CKD) Drugs Market, By Drug Class
6.1 Introduction
6.2 Calcium channel blockers
6.3 Antihypertensive
6.4 Anemia Treatment Drugs
6.5 Antihyperlipidemic
6.6 Erythropoiesis-stimulating agents (ESAs)
6.7 Swelling Treatment Drugs
6.8 Beta blockers
6.9 Diuretics
6.10 Angiotensin-II receptor blockers
6.11 ACE Inhibitors
6.12 Other Drug Classes

Continued…..

For more information or any query mail at sales@wiseguyreports.com

About Us
Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.

Contact Us:
Norah Trent
+1 646 845 9349 / +44 208 133 9349
Follow on LinkedIn: https://www.linkedin.com/company/wise-guy-research-consultants-pvt-ltd-?trk=biz-companies-cym

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire